Practical guidance for national influenza centres establishing or implementing neuraminidase inhibitor susceptibility surveillance

Updated 2018



Practical guidance for national influenza centres establishing or implementing neuraminidase inhibitor susceptibility surveillance, updated 2018

ISBN 978-92-4-151666-2

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <u>https://creativecommons.org/licenses/by-nc-sa/3.0/igo</u>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Practical guidance for national influenza centres establishing or implementing neuraminidase inhibitor susceptibility surveillance, updated 2018. Geneva: World Health Organization; 2019. Licence: <u>CC BY-NC-SA 3.0 IGO</u>.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see <u>http://apps.who.int/bookorders</u>. To submit requests for commercial use and queries on rights and licensing, see <u>http://www.who.int/about/licensing</u>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland.

Contents

Abbreviations and acronymsiv
Summaryv
1. Surveillance systems and specimen selection7
1.1 AVST of community specimens7
1.2 AVST of hospital specimens9
1.3 AVST of severe acute respiratory infection specimens9
1.4 AVST of specimens from specific groups or situations10
2. Choice of methodologies10
3. Reference materials and quality11
3.1 Phenotypic NI assays11
3.1.1 CDC Neuraminidase inhibitor susceptibility reference virus panel (version 2.0)11
3.2 Genotypic molecular-based assays12
3.3 External Quality Assessment Project12
4. Algorithm and actions for unusual results12
5. Reporting of NAI susceptibility data14
6. Training tools and resources16
6.1 Online tools and resources16
7. Laboratory self-evaluation17
Annex 1. Laboratory self-evaluation Checklist18
References

Abbreviations and acronyms

AVST	antiviral susceptibility testing			
СС	collaborating centre (WHO)			
CDC	Centers for Disease Control and Prevention			
GISAID	Global Initiative on Sharing All Influenza Data			
GISRS	Global Influenza Surveillance and Response System			
HRI	highly reduced inhibition			
IC ₅₀	half maximal inhibitory concentration			
IRR	International Reagent Resource			
MTA	materials transfer agreement			
NA	neuraminidase			
NAI	neuraminidase inhibitor			
NI	neuraminidase inhibition			
NIC	national influenza centre			
PCR	polymerase chain reaction			
RI	reduced inhibition			
RT-PCR	reverse transcription-polymerase chain reaction			
SARI	severe acute respiratory infection			
SNP	single-nucleotide polymorphism			
TESSy	The European Surveillance System			
WHO	World Health Organization			

Summary

Surveillance of influenza antiviral susceptibility has become more important as use of antivirals has increased, and it now plays an important role in influenza control procedures. Antiviral surveillance capability within Global Influenza Surveillance and Response System laboratories is required to ensure good coverage in each World Health Organization region. However, there is debate about the scale of testing required; in contrast to virus detection, there is no expectation that every laboratory should perform antiviral susceptibility testing (AVST). Some national influenza centres wish to implement antiviral surveillance, but are not fully aware of the laboratory requirements for such surveillance.

All influenza surveillance systems and effective control measures, whether national or international, depend on the consistent and successful implementation of key laboratory activities. The implementation of AVST in a laboratory depends on factors such as available expertise, financial resources and facilities; it also depends on overcoming any difficulties in acquiring or importing the necessary equipment and consumables, or in establishing equipment maintenance contracts.

This document discusses the practical considerations that must be assessed when deciding whether implementation of AVST within a laboratory is practical, the long-term costs of testing, and the requirements for testing in terms of resources (both equipment and reagents) and staff training.

A checklist given at the end of the document allows a simple self-assessment of whether a laboratory can establish and maintain AVST capability.

1. Surveillance systems and specimen selection

In surveillance systems and specimen selection, the first thing to note is that antiviral susceptibility testing (AVST) should be integrated into existing surveillance systems rather than being a stand-alone activity. Consequently, laboratories that intend to establish AVST need to consider the surveillance systems that are already in place. This will allow laboratories to ensure that they receive relevant specimens and complementary information (epidemiological and clinical) for analyses and upload of data to existing systems. When establishing AVST, it is crucial to set priorities for which specimens to test, as shown in Table 1, in order to implement a cost-effective strategy while simultaneously meeting surveillance requirements. National influenza centres (NICs) need to adopt the best strategy, based on their existing capacity, to fulfil their objectives and requirements, taking into account AVST of community, hospital and severe acute respiratory infection (SARI) specimens, and of specimens from specific groups or situations.

1.1 AVST of community specimens

The collection of specimens from patients presenting to health care systems is an essential routine component of national networks for influenza surveillance. This surveillance, based on randomly selected influenza virus positive samples, is of epidemiological importance because it makes it possible to determine:

- baseline antiviral susceptibility among circulating viruses; and
- the frequency of viruses with reduced inhibition (RI) or highly reduced inhibition (HRI), or those carrying amino acid substitutions associated with resistance or RI/HRI, which can be used to identify trends.

Specimens from the untreated community are the most important for determining changes in resistance or RI/HRI, because the number of viruses exhibiting resistance or RI/HRI can be put into context more easily than is the case with specimens from treated patients. Ideally, such specimens should come from a community sentinel surveillance scheme in which basic clinical information can be collected and patients can be followed up. If no such scheme is in place, non-sentinel community specimens should be tested. The number of specimens that should be tested will depend on the number of positive specimens received and the laboratory capacity, which may change from year to year. For comprehensive surveillance by any method, samples selected for testing should be distributed throughout the influenza season.

For phenotypic (half maximal inhibitory concentration – IC_{50}) testing, a minimum target of 40 viruses, covering all types and subtypes, is ideal. This will ensure that sufficient data are available for development of seasonal and subtype-specific criteria for identification of unusual viruses. For both genotypic and phenotypic testing, randomly selected specimens spanning the entire influenza season should be tested, based on the date of disease onset (if known) or the date of sample collection. If laboratory capacity allows, at least the first 10 viruses of each type and subtype should be tested, reducing to a reasonable proportion (10–20%) of virus isolates during the season peak. At the end of the season, when the number of isolates is below 10 per week, most isolates should be tested.

The data collected from AVST of community specimens are important from a public health perspective, because they provide information on whether viruses displaying RI/HRI can undergo sustained transmission in the community and retain the ability to cause disease. The data emerging can lead to public health actions, such as the periodic revision of guidelines (e.g. for antiviral treatment and chemoprophylaxis) and the issuing of alerts to scientific and clinical communities.

Type of specimen	Purpose	Necessity	Number and timing of specimens		
Sentinel specimens	 Determines a baseline of susceptibility in circulating viruses Determines the frequency of viruses that are resistant or show 	Highly desirable	Random selection based on laboratory capacity: • 40 minimum • selected throughout a season to include the first 10 of each (sub)type, followed by every fifth		
	RI/HRI; essential for informing national and international policy on neuraminidase inhibitor use		isolate throughout a season • majority when detections fall below 10 per week		
Non-sentinel specimens					
Type of patient	Patient characteristics	Necessity	Timing of specimens		
Immunocompromised patients (treated)	 Likelihood of prolonged virus shedding Likelihood of high virus load 	Where available	Pre- and post-treatment specimens from each patient, and ongoing specimens if the patient is found to be shedding virus over a prolonged period of time		
Patients becoming influenza positive during or after receiving postexposure prophylaxis	Insufficient drug dose increases the likelihood of resistance emergence	Where available	Earliest and latest influenza positive specimens		
Any treated patients, but especially those with prolonged therapy or shedding	Determines the frequency of resistant viruses emerging under treatment	Where available	Pre- and post-treatment; monitor for duration of virus shedding		
Severe cases	Monitors for any changes in clinical impact or epidemiology associated with resistance	Highly desirable	Selected specimens over the duration of virus shedding		
Fatal cases	Monitors for any changes in clinical impact or epidemiology associated with resistance	Highly desirable	Earliest and latest influenza positive specimens		
Outbreaks (e.g. in care or nursing	Higher probability of close contact and localized	Highly	Selected early, mid and late		

Table 1. Specimen sources important for antiviral susceptibility surveillance

预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5_25944